Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy
01/08/2026 07:00 AM • Lexeo Therapeutics announced a research collaboration with Johnson & Johnson to investigate localized cardiac delivery of AAV gene therapy using Impella heart pump technology. The partnership aims to improve the efficacy and safety of gene therapy for genetically mediated cardiovascular diseases by concentrating viral delivery to the heart while reducing required AAV doses.
LXEO - The company announced a strategic collaboration with a major pharmaceutical leader (Johnson & Johnson) to advance its cardiac gene therapy platform. This partnership validates Lexeo's technology, provides access to complementary expertise and established cardiovascular technologies, and accelerates development of preclinical cardiac targets, which are positive indicators for the company's pipeline and market potential.
Investing.com • Fawad Razaqzada